Dec 07, 2021 / 01:30PM GMT
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Vir Conference Call. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Ms. Heather Rowe Armstrong. Please go ahead, Ms. Heather.
Heather Rowe Armstrong - Vir Biotechnology Inc. - VP, IR
Thank you, operator, and thank you all for joining us today for this important update on sotrovimab's role in neutralizing Omicron variant. My name is Heather Armstrong, and I'm the Vice President of Investor Relations at Vir. Joining me today are George Scangos, Ph.D. and Chief Executive Officer; Skip Virgin, M.D., Ph.D. and our Chief Scientific Officer; and Howard Horn, our Chief Financial Officer. The materials we will be referencing on today's conference call can be found under the Events section of the Investors page of our website.
Before we begin, let me remind you that some of the statements we will make on this call today are forward-looking statements. These include statements that are not historical facts. These forward-looking statements,
Vir Biotechnology Inc Corporate Call on Sotrovimab's Retained Activity Against the Omicron SARS-CoV-2 Variant Transcript
Dec 07, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers